Navigation Links
China YCT International Group, Inc. Announces Entrusted Management Agreement With Its Primary Supplier
Date:4/7/2008

NEW YORK, April 7, 2008 /Xinhua-PRNewswire-FirstCall/ -- China YCT International Group Inc. (OTC Bulletin Board: CYIG) today announced that its wholly owned subsidiary, Shandong Spring Pharmaceutical Co., Ltd, has entered into an Entrusted Management Agreement with Shandong Yong Chun Tang Bioengineering Co. Ltd., effective as of April 4, 2008. The agreement provides that Shandong Spring Pharmaceutical will manage the operations of Shandong Yong Chun Tang, in exchange for all of the net profits earned by Shandong Yong Chun Tang. Shandong Yong Chun Tang is the primary supplier of products marketed by Shandong Spring Pharmaceutical. The companies also announced that they intend to enter into a strategic relationship to integrate and distribute Shandong Yong Chun Tang's gingko products using Shandong Spring Pharmaceutical's advanced logistics solutions.

At the same time, the parties entered into a Purchase Option and Cooperation Agreement with Yan Tinghe, who is the Chairman of China YCT International Group, Inc. and principal owner of Shandong Yong Chun Tang. The Purchase Option gives Shandong Spring Pharmaceutical the right to purchase Shandong Yong Chun Tang at a fair value price to be determined by the parties at the time the option is exercised. Mr. Yan also gave to Shandong Spring Pharmaceutical a proxy to exercise his voting rights as a shareholder of Shandong Yong Chun Tang.

Commenting on the announcement, Yan Tinghe, Chairman of China YCT International Group, Inc., said, "Today's agreement accomplishes our goal of focusing our organization, while also establishing a long-term relationship with Shandong Spring Pharmaceutical., Ltd that will be beneficial to both companies. Our newly distribution management team, professional staff, and financial resources can now concentrate on establishing meaningful market share, awareness, and industry appreciation for gingko products."

Commenting on the synergies of the companies' planned strategic relationship for Shandong Spring Pharmaceutical Co, Ltd., Mr. Yan said, "Customers are looking for product sets that provide practical solutions to the health needs, and fast and safe delivery. Being able to provide a distribution management solution that is tightly coupled with the high-tech production will provide our common customers with a significant advantage."

Shandong Spring Pharmaceutical was organized in 2005 under the laws of The People's Republic of China. From January 2006 until January 2007 management was engaged in developing the company's manufacturing facility and distribution network. In January 2007 Shandong Spring Pharmaceutical commenced revenue-producing activities; specifically distributing products manufactured by Shandong Yong Chun Tang.

Shandong Spring Pharmaceutical was originally organized as a subsidiary of Shandong Yong Chun Tang for the purpose of focusing on advanced technology related to the use of gingko as an aide to health. Shandong Yong Chun Tang later transferred ownership of Shandong Spring Pharmaceutical to its equity-holders. Nevertheless the business plan remains focused on developing a fully-integrated business engaged primarily in the application of advanced biological engineering technology to the growth and refining of gingko and the use of its constituent compounds in products that will provide health benefits and/or cosmetic advantages.

This press release includes forward-looking statements that involve risks and uncertainties, including, but not limited to, quarterly fluctuations in results, the management of growth, the ability to fund operations, and other risks detailed from time to time in the Company's Securities and Exchange Commission filings. Actual results may differ materially from management expectations.

About China YCT International Group, Inc.

China YCT International Group, Inc. engages in the development, manufacture, and marketing of gingko products and other dietary supplement products in the People's Republic of China. The company was formerly known as ItLinkz Group, Inc. and changed its name to China YCT International Group, Inc. in November 2007.


'/>"/>
SOURCE China YCT International Group Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. China Medical Technologies to Participate in the Morgan Stanleys 2007 China Medical Corporate Day
4. China-Biotics, Inc. Signs Intention Agreement to Supply Probiotics to Bright Dairy & Food Co., Ltd.
5. China Technology Announces New Chief Financial Officer
6. China Medical Technologies Reports First Quarter Financial Results
7. China Medical Technologies to Participate in Credit Suisses 2007 Asian Technology Conference
8. China Technology Announces Entry to the Solar Energy Sector
9. China Sky One Medical Receives $1.5 Million Government Grant to Further Develop Six New Cancer Products
10. Kiwa Bio-Tech Named Recommended Brand by the China Green Food Association
11. China Kangtai Cactus Biotech, Inc. Announces Plans for New Product Launch
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... GAITHERSBURG, Md. , Jan. 19, 2017 ... Inc., a privately-held immunotherapeutics company targeting infectious diseases, ... for the merger of PharmAthene and Altimmune in ... Venture Fund, HealthCap, Truffle Capital and Redmont Capital. ... diversified immunotherapeutics company with four clinical stage and ...
(Date:1/19/2017)... ... January 18, 2017 , ... ... innovators, engineers, and scientists from around the world, was today awarded the "Best ... program is based entirely on merit and decided upon by a dedicated team ...
(Date:1/19/2017)... Jan. 18, 2017  Northwest Biotherapeutics, Inc. (OTCQB: NWBO) ... immune therapies for operable and inoperable solid tumor cancers, ... Technical Officer of NW Bio, will present at the ... at the Hyatt Regency Hotel in Miami, ... the session entitled "New Therapeutic Approaches – Expanding the ...
(Date:1/18/2017)... According to a new market research report "In situ Hybridization Market ... User (Molecular Diagnostic Laboratories, Academic and Research Institutions) - Global Forecast to 2021" ... 2021 from USD 557.1 Million in 2016, growing at a CAGR of 5.8%. ... ... MarketsandMarkets Logo ...
Breaking Biology Technology:
(Date:12/16/2016)... , Dec 16, 2016 Research and Markets ... Market - Global Forecast to 2021" report to their offering. ... The biometric ... grow at a CAGR of 14.06% from 2016 to 2021. The ... is projected to reach 854.8 Million by 2021. The growth of ...
(Date:12/15/2016)... ... and Markets has announced the addition of the "Global Military Biometrics ... forecasts the global military biometrics market to grow at a CAGR of ... prepared based on an in-depth market analysis with inputs from industry experts. ... coming years. The report also includes a discussion of the key vendors ...
(Date:12/12/2016)... 12, 2016  Researchers at Trinity College, Dublin, ... by combining the material with Silly Putty. The mixture ... detector able to sense pulse, blood pressure, respiration, ... The research team,s findings were ... here:  http://science.sciencemag.org/content/354/6317/1257 ...
Breaking Biology News(10 mins):